Expansion Opportunity Recent facility expansions in India (Bangalore) and Hyderabad indicate capacity growth and capability to transfer programs to cost-efficient manufacturing, presenting opportunities to offer end-to-end development to accelerate scale-up and reduce COGS for biologics clients.

Platform Strength Robust cell line development with royalty-free and milestone-free CHO platform delivering high titers (up to 5 g/L in 5 months) and multiple cell lines producing marketed products, suggesting strong potential for partners needing rapid, scalable expression systems for challenging biologics.

Specialized Expertise Deep experience in complex formats, bi- and multi-specific antibodies, and non-antibody proteins, coupled with a history of staff from top institutions, positioning Aragen as a favorable partner for hard-to-develop therapeutics and early-stage discovery programs.

Strategic Growth Investments in leadership and technology (RapTr 2022 platform launch; key hires) signal a growth trajectory and enhanced capabilities, providing sales angles around expanded service breadth, faster timelines, and improved program risk management.

Global Collaboration Geographic expansion paired with manufacturing transfer capabilities enables international customers to localize development and production, offering a compelling value proposition for global biologics programs seeking regionalized CRO support and cost efficiencies.